Management preferences in stage I non-seminomatous germ cell tumours of the testis: an investigation among patients, controls and oncologists. by Cullen, M. H. et al.
British Journal of Cancer (1996) 74, 1487-1491
© 1996 Stockton Press All rights reserved 0007-0920/96 $12.00 %
Management preferences in stage I non-seminomatous germ cell tumours of
the testis: an investigation among patients, controls and oncologists
MH Cullen', LJ Billingham2, J Cook2 and CM Woodroffe2
'Birmingham Oncology Centre, University Hospital, Birmingham NHS Trust, Birmingham B15 2TH, UK; 2CRC Trials Unit,
Institute for Cancer Studies, University ofBirmingham, UK.
Summary Increasingly, treatment choices leading to the same survival outcome can be offered to cancer
patients (e.g. mastectomy or conservative surgery in early breast cancer). Two approaches available for post-
orchidectomy, stage I patients with non-seminomatous germ cell tumours of the testis (NSGCTT), particularly
those at high risk of relapse, include immediate adjuvant chemotherapy (two courses) or surveillance, with
chemotherapy (typically four courses) given only on relapse. The aim of this study was to investigate which
approach patients prefer. Questionnaires were given to newly diagnosed NSGCTT patients, to patients with
previous experience of the two options and to non-cancer controls, including specialist testicular tumour
oncologists. Participants were asked to choose between immediate chemotherapy, surveillance or for the doctor
to decide, at recurrence risk levels ranging from 10% to 90%. Questionnaires were returned by 207 subjects in
nine different groups. The risk thresholds at which subjects' management preference changed, within apparently
homogeneous groups, varied greatly, although at least one subject in each group selected adjuvant
chemotherapy at the lowest (10%) level of risk. Subjects tended to favour options of which they had previous
experience. Cancer patients wanted the doctor to decide more frequently than controls. The wide variability
observed makes it difficult to predict which option an individual will select. Personality factors and personal
circumstances, other than specific experience and knowledge,-are obviously influential. Many patients would
prefer their doctor to decide, but variability among oncologists is as great as that among their patients.
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Following surgical removal of the primary tumour, patients
with stage I non-seminomatous germ cell tumours of the
testis (NSGCTT-'testicular teratoma') have an overall risk
of developing metastatic disease of 30% (Cullen, 1991).
However, a subgroup of these patients, which can be
identified histologically, has an increased risk of distant
recurrence of 50% (Freedman et al., 1987). A recent MRC
study has demonstrated that two courses of chemotherapy,
administered not more than 6 weeks after surgery, will
increase relapse-free and long-term survival rates to more
than 98% in this 'high-risk' subgroup (Cullen et al., 1996).
Stage I cases who are managed in a surveillance programme,
with chemotherapy (typically four courses) reserved for those
patients who relapse, enjoy an identical long-term survival
rate (Read et al., 1992). Thus, there is a choice of two
different management approaches for high-risk stage I
teratoma patients; either immediate adjuvant chemotherapy,
or the surveillance programme with chemotherapy only given
on relapse. Both approaches lead to the same, excellent,
survival prospects for this group of patients, but their
attendant shortcomings are different.
It is clear that some patients experience anxiety as a result
of the uncertainty of surveillance (Moynihan, 1987).
Prompted by this, we sought to investigate which manage-
ment approach patients prefer. Newly diagnosed teratoma
patients were asked to imagine risks of recurrence ranging
from 10% to 90% and then to choose between: immediate
adjuvant chemotherapy (AC); surveillance (S); or for the
doctor to make the decision (DD), at each risk level.
We also presented the same hypothetical scenario to
different groups of controls, namely: subjects with the
'ultimate' experience, i.e. patients with testicular teratoma
who have been through a surveillance programme, and others
who have been treated with chemotherapy; those who might
be considered to have the 'ultimate' knowledge, i.e. specialist
testicular tumour oncologists; and two other groups of non-
cancer controls.
Subjects and methods
Nine separate groups, which might reasonably be expected to
respond differently owing to varying experience or knowl-
edge, were studied:
1. Newly diagnosed patients with stage I NSGCTT (New;
n = 18). For this group it was a 'real-life' situation.
Patients completed the questionnaire before their indivi-
dual recurrence risk had been established.
2. Patients with stage I NSGCTT who had completed an 18
month surveillance programme without recurrence (Post-
surv; n=I1).
3. Patients with stage I NSGCTT who were under
surveillance (for a median of 7 months) within 18 months
of diagnosis (Surv; n = 16).
4. Patients with stage I NSGCTT who had completed two
courses of adjuvant BEP chemotherapy, having been
diagnosed as high-risk stage I NSGCTT (AC; n = 6).
5. Patients with metastatic NSGCTT who had completed
four courses of BEP chemotherapy with no evidence of
recurrence (BEP4; n = 31).
6. Patients with stage I NSGCTT who had experienced
surveillance, but then relapsed and undergone BEP
chemotherapy and were in remission, presumed cured
(Relsurv; n =9).
7. Non-cancer controls- 1; medical students having just had
a lecture on NSGCTT (Students; n = 56).
8. Non-cancer controls-2; firemen (Firemen; n = 37). All the
available officers at one fire station were selected.
9. Non-cancer controls -3; Specialist testicular tumour
oncologists (Oncol; n = 18). These were all the oncologist
members of the MRC testicular tumour working party
responsible for managing the vast majority of cases in the
UK.
A specifically trained oncology nurse was responsible for
administering a detailed information sheet and questionnaire to
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all those testicular teratoma patients attending the outpatient
clinic of one consultant (MC), over a period of a year. The
information sheet describes the background and management
options clearly, including likely short- and long-term side-
effects. The oncologists were sent the same information sheet
and questionnaire through the post. The two other control
groups, medical students and firemen, were approached via a
group lecture on the disease, followed by administration ofthe
information sheet and questionnaire. The first part of the
questionnaire recorded demographic information such as age,
marital status, number ofchildren, plans to have children and
experience of serious illness. The second part of the
questionnaire then asked which management approach the
individual would choose given the hypothetical risks of
secondaries of 10%, 20%, 30%, 40%, 50%, 70% and 90%.
In the current state ofknowledge itis notpossible todistinguish
groups with a recurrence risk of 70% or 90%, but these were
included as an internal control to help assess how well the
participants had understood to exercise.
Intuitively, surveillance is likely to be more popular at
lower levels of risk, and chemotherapy at the upper levels.
Making a firm selection for oneself is likely to be easiest at
the extremes of risk with the third option (i.e. for the doctor
to decide) being selected in the middle ranges.
The date were investigated in two ways. Firstly, for each
group, the number of participants selecting the three options
was plotted against each recurrence risk as line graphs. These
are referred to as 'group trends'. Secondly, to observe trends
within subjects and also to facilitate comparisons between
groups, three response variables of interest were derived from
the questionnaire data. These are called 'subject trends':
(1) Surveillance limit (see example below). This is the upper
limit of range of risk for which the subject chooses the
surveillance option. A subject is assumed to want
surveillance right up to the point at which he chooses
the chemotherapy or doctor decide option.
(2) Chemotherapy limit. This is the lower limit of range of
risk for which the subject chooses the chemotherapy
option.
(3) Uncertainty range. This is the range of risk between
which the subject prefers the doctor to decide. For those
subjects who never select this option (1) and (2) will be the
same.
Example
10 20 30 40 50 70 90
S S DD DD AC AC AC
Surveillance Chemotherapy
limit limit
Uncertainty
range
The data for (1) and (2) are illustrated using box and whisker
plots. These give the whole range of limits selected by that
group (the whiskers), the middle 50% of values (in the box)
and the median. The data for (3) are illustrated using a plot
which shows, for each group, the median lower and upper
risk levels of the uncertainty range. The effect of age on
response in the whole group of participants was investigated
using Spearman's correlation coefficient, while the effect of
marital status and having children was investigated using
Wilcoxon tests. The difference in response between male and
female medical students was investigated using a Wilcoxon
test. A 5% level of statistical significance was used.
Results
Questionnaires were completed by 207 subjects from nine
different populations. The presence of the research nurse was
felt to have contributed to the high compliance rate of 98%.
The responses given by five individuals (from a variety of
groups) clearly suggested that they had misunderstood the
questionnaire and so they were eliminated from the analysis.
Table I shows the background information for the 202
individuals.
Group trends
The group trends are shown for three selected groups of
subjects - newly diagnosed cases (Figure 1), patients who
had personal experience of four courses of chemotherapy
(Figure 2) and patients who have previous experience of
surveillance (Figure 3). In all groups, as the level of risk
increased, the number opting for adjuvant chemotherapy
increased and the number choosing surveillance decreased.
The new patients and post-chemotherapy patients
responded to the hypothetical scenario in a very similar
fashion, except that the level of risk above which the
preference for chemotherapy became clear was higher in the
new patients compared with the post-chemotherapy patients
(30% and 20% respectively). In both these groups the
number choosing the doctor decide option was greatest at the
lower levels of risk, peaking at the 20% risk.
The picture for patients who have previous experience of
surveillance is rather different. In this group, the level of risk
above which the preference for chemotherapy was clear was
higher, at 50%, and the number choosing the doctor decide
option was greatest at the 40% and 50% levels of risk.
In all three groups ofpatients, approximately 25% selected
adjuvant chemotherapy even at the lowest (10%) level of risk.
Subject trends
Surveillance limit The surveillance limit is defined as the
upper limit of range of risk for which the subject chooses the
surveillance option (Figure 4).
The range of choice within each group is wide. At least
one individual in each group preferred to avoid surveillance
even at the lowest 10% risk of recurrence. On the other hand,
two oncologists and one BEP4 patient preferred surveillance
throughout the range, including the highest risk of 90%. The
upper surveillance limit for all other groups was 70%, except
those cases with high-risk stage I NSGCTT, who had been
managed with adjuvant chemotherapy (AC), in whom it was
50%.
The median surveillance limit was lowest (10%) for those
patients who had previously relapsed on surveillance and the
adjuvant chemotherapy group. The median limit was 20% for
the new stage I patients and those previously treated with
four courses. The highest median surveillance limit (40%), i.e.
those apparently most in favour of this policy, was observed
Table I Background information
Number (%)Number (%)
Number of Median marriedl with
n women age (range) cohabiting no children
New 18 - 35 (24-44) 10 (56%) 8 (44%)
(2 unknown)
Postsurv 11 - 41 (21-57) 5 (46%) 3 (27%)
Surv 16 - 31 (23-60) 8 (50%) 11 (69%)
[1 unknown]
AC 6 _ 30 (24-53) 3 (50%) 1 (17%)
[1 unknown)
BEP4 31 - 31 (21-49) 19 (61%) 15 (48%)
(3 unknown)
Relsurv 9 - 31 (23 -37) 4 (67%) 2 (33%)
[2 unknown) (3 unknown) (3 unknown)
Students 56 32 (58%) 22 (21-29) 3 (5%) 56 (100%)
(1 unknown) (1 unknown)
Firemen 37 - 42 (30-52) 34 (94%) 4 (11%)
(1 unknown) (1 unknown)
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Figure 1 Number of patients selecting each option at specified
risk levels (n = 18).
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Figure 4 Surveillance limit for each group - box and whisker
plot showing median, interquartile and full ranges. Key to groups
in text. Median shown by heavy line, interquartile range by box
and full range by whiskers.
Group
Figure 5 Chemotherapy limit for each group- box and whisker
plot showing median, interquartile and full ranges. Key to groups
in text. Median shown by heavy line, interquartile range by box
and full range by whiskers.
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Figure 2 Number of post-chemotherapy patients (BEP4)
selecting each option at specified risk levels (n=31).
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4 Immediate adjuvant chemotherapy
-4- Doctor to decide
A A
one subject did not select adjuvant chemotherapy even when
6 - '_ ./ the risk of secondaries was as high as 90%. The variability is
5 - ^\ ,^ + such that even the middle 50% of limits chosen (i.e. the box
part of Figure 5) lie in ranges of 30% or more.
The median recurrence risk at which subjects choose
adjuvant chemotherapy is lowest (25%) for those who have
c , ,, I | j ^ ^ had that management policy (AC), is 30% for the medical
10 20 30 40 50 70 90 students and firemen, 40% for the oncologists, newly
Risk of secondaries ( diagnosed stage I and BEP4 patients and as high as 70%
for patients on surveillance or who have completed
I Number of post-surveillance patients selecting each surveillance.
Uncertainty range The uncertainty range is defined as the
range of risk within which the subject prefers his doctor to
decide which treatment schedule to follow.
The proportion of participants wanting the doctor to
decide on management for at least one of the decision points
is shown in Table II. Not surprisingly, the control groups
have the lowest proportions of respondents making this
choice, particularly the oncologists and medical students with
fewer than 10%. In the other groups, all of whom have or
have had testicular cancer, between 33% and 64% opted for
the decision to be made by the doctor at one or more risk
levels.
The range of uncertainty was narrow and identical (30-
40%) for the oncologists and medical students (Figure 6).
The other groups were uncertain over a broader range,
- -cb-- - --_ -- J_r,
option at specified risk levels (n= 11).
in the patients on surveillance and the oncologists. In the
remaining three groups (including the students and firemen)
the median limit for choosing surveillance was 30%.
Chemotherapy limit The chemotherapy limit is the lower
limit of range of risk for which the subject chooses the
chemotherapy option (Figure 5).
Again the range is very wide among all groups extending
from 10% to >90% in all but three. Each group has at least
one subject choosing chemotherapy at the lowest (10%)
recurrence risk, and, with the exception of the students, the
adjuvant chemotherapy group and the new patients, at least
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Table II Proportion ofeach group who wanted the doctor to decide
at some level
Numberl
total Percentage
New 8/18 44
Post-surveillance 7/11 64
Surveillance 7/16 44
Adjuvant chemotherapy 2/6 33
BEP4 12/31 39
Relapse on surveillance 5/9 56
Students 5/56 9
Firemen 6/37 16
Oncol 1/18 6
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Figure 6 Median start and end points of the uncertainty range
for each group.
extending between 10% and 90%, but with notable
differences in pattern between groups. The uncertainty range
for new patients and those who had four courses of BEP was
at a lower level than the other patient groups. The range of
uncertainty was widest in the patients who relapsed on
surveillance (30-90%).
Association of response with background information
No significant differences were found between male and
female medical students in terms of the surveillance limit
(P=0.83) and the chemotherapy limit (P=0.93). For all
participants, age and marital status did not appear to be
associated with the surveillance limit (P=0.83 and P=0.38
respectively) or the chemotherapy limit (P=0.29 and 0.86
respectively). Although the result did not reach statistical
significance (P=0.06), there was some evidence to suggest
that having no children affected the surveillance limit, with
those having no children choosing surveillance up to higher
levels of risk compared with those who already had a family.
The existence of children was not found to have an effect on
the chemotherapy limit (P=0.73).
Discussion
The recently published Expert Advisory Group on Cancer
Report (1995) stresses the importance of giving patients clear
information about treatment options. However, we know
very little about how patients use such information in
decision making (Richards et al., 1995) and most of the
available data relate to early breast cancer (Fallowfield et al.,
1994). Increasingly, there are therapeutic alternatives for
cancer patients and choices to be made. The present study
was originally conceived as an attempt to determine which, of
two treatment options with the same outcome, would be
preferred by the majority ofpatients with testicular teratoma.
Control groups were included to test the validity of the
questionnaire and information sheet. The responses resulting
from the questionnaire have proved to be more interesting
and thought provoking. They provide an insight into the
degree to which patients are able to comprehend, and use,
statistical information; how far they wish to be involved in
the decision making process and to what extent related
experience and knowledge may influence choice.
It was felt that the inappropriate responses of 5 of the 207
subjects (3%; four patients, one control) were an indication
that they had misunderstood the exercise. (These subjects had
opted for chemotherapy at the lower risk levels and had also
chosen surveillance at the upper levels.) This surprisingly low
failure rate was probably due to the presence of a trained
nurse specialist to administer and explain the questionnaire to
all but the oncologist group, and to the use of carefully
worded information sheet which had been piloted before the
main study.
A number of other studies of patient participation in
decision making clearly show that many patients prefer key
decisions to be made by the doctor (Cassileth et al., 1980;
Davison et al., 1996). In the present study very few
participants in the non-cancer control groups opted for the
doctor to decide, and, in particular, the medical students and
oncologists had very narrow limits of uncertainty. The other
non-cancer control group, the firemen, have a slightly higher
tendency to delegate the decision to the doctor than the
medical students, but much less than the only other group
with no experience of testicular cancer and its treatment (the
newly diagnosed patients). The patients, in contrast, quite
frequently opted for the doctor to decide - even those
patients who had first-hand experience of at least one of
the management options. This accords well with the findings
of others that individuals seem to have more difficulty
making decisions concerning cancer treatment when it applies
to them, than when it is purely hypothetical (Degner and
Sloan, 1992). However, in the present study it was essentially
a hypothetical scenario for the patient groups who had
completed treatment. These, too, frequently selected the
doctor decide option. To what extent this reflects choice
which is conditioned by the submissive patient role
(Thornton, 1995), or to a more valid relinquishing of
autonomy based perhaps on trust in the physician, cannot
be assessed with the data discussed here.
The most striking outcome of this study is the wide
variability of response within groups, with a greater
consensus with regard to surveillance than there is for
selecting chemotherapy. Interestingly, taking both criteria
together, the group with the widest range of response is the
specialist oncologists. Hence, 'ultimate knowledge' does not
focus choice within narrow ranges; if anything, it has the
opposite effect.
To examine the roots of this variability, it would be
necessary to evaluate and compare personality traits,
particularly those involved in influencing risk assessment,
across the groups, in an attempt to detect parallels. The
results described here were unexpected and hence this exercise
was not undertaken. Studies of patient choice in the future
should include this component.
As well as parallels, there are obvious differences between
the groups. The small group of cases who had been managed
with adjuvant chemotherapy is the group with the lowest
median minimum risk at which that option is selected and
are, therefore, apparently most in favour of this policy.
Conversely, the group with previous experience of surveil-
lance is the one requiring the highest recurrence risk before
choosing chemotherapy. There are two possible explanations,
which are not mutually exclusive: firstly, the patients may
have been content with the option they have experienced and
so would choose it again; secondly, the patients may select
that option because it was how they were managed and they
are reluctant to contemplate missing an alternative that was
not offered, but might have been preferable. It is impossible,
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within the data presented here, to quantify the relative
importance of these. The similarities between the groups are,
perhaps, more interesting. Considering the chemotherapy
limit (Figure 5), the newly diagnosed patients, the testicular
tumour specialists, and the patients with experience of four
courses of BEP have identical medians and very similar
(wide) distributions of response. These three groups could
hardly be more different in their background, present
predicament and previous experience. Likewise, with the
surveillance limit criterion (Figure 4), the medical students,
firemen and post-surveillance groups are similar with respect
to median and range, but have little else in common.
The implication of these findings is that germane
experience and knowledge have less influence on decision
making than other factors. These factors are likely to be
linked to differences in personality that may be common to
all groups. Therapeutic research tends to be directed towards
identifying a single best management strategy for each
disease situation. Perhaps, instead, we should be prepared to
accept that, as the range of treatment options widens, there
may no longer be a best option for a particular patient
population, but rather an optimum management plan for
each individual. As treatment improves it will become more
important to offer patients alternative strategies, with similar
principal outcomes, and to help those who wish to choose
for themselves to do so. At the same time we must recognise
that some will wish to delegate these decisions to doctors
who, in turn, will have as broad a range of personalities,
and hence favour as diverse a range of choices as their
patients.
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